Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc (NASDAQ: BCYC) is a clinical-stage pharmaceutical company developing Bicycle molecules, Bicycle Drug Conjugates (BDC) and Bicycle Radioconjugates (BRC) for oncology indications. News about BCYC often centers on progress across its clinical pipeline, strategic collaborations, and financial updates that shape the company’s development plans.
Investors and observers following BCYC news can expect regular updates on clinical trials such as the Duravelo-1 Phase 1 study, the Duravelo-2 Phase 2/3 pivotal trial in metastatic urothelial cancer, and the Duravelo-3 and Duravelo-4 Phase 1/2 studies in Nectin-4–amplified breast cancer and non-small cell lung cancer. The company also reports on data presentations at major scientific meetings, including imaging and clinical data for BRC molecules targeting EphA2 and MT1-MMP.
Company news also covers strategic partnerships, including long-term arrangements with the UK Nuclear Decommissioning Authority, the United Kingdom National Nuclear Laboratory, and SpectronRx to support an end-to-end 212Pb radiopharmaceutical supply chain. Additional announcements highlight Board of Directors changes, formation and expansion of the Research and Innovation Advisory Board, and inducement grants to new employees under the 2024 Inducement Plan.
On this BCYC news page, readers can track press releases on quarterly financial results, regulatory interactions related to zelenectide pevedotin’s potential approval pathway, and anticipated milestones such as dose selection decisions and data disclosures. For those researching Bicycle Therapeutics stock, this news feed provides a centralized view of the company’s operational, clinical, and corporate developments over time.
Bicycle Therapeutics plc (NASDAQ: BCYC) has announced the publication of preclinical data for BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, in the Journal of Medicinal Chemistry. This study, alongside previous research, supports BT8009's development for treating Nectin-4 expressing tumors, which are prevalent in various solid cancers. The company is currently evaluating BT8009 in a Phase I/II clinical trial. Bicycle's innovative Bicycle technology aims to create effective therapies for underserved cancer indications.
Bicycle Therapeutics plc (NASDAQ: BCYC) announced the publication of preclinical data for BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, in Molecular Cancer Therapeutics. The article details its efficacy in killing solid tumor cells, with significant tumor regression observed in various models. The results follow positive interim findings from its Phase I trial, which suggest BT8009's potential for treating solid tumors effectively. Additional clinical data is expected later this year, underscoring the drug’s promising development trajectory.
Bicycle Therapeutics (NASDAQ: BCYC) announced promising Phase I results for BT5528, targeting EphA2 in patients with advanced solid tumors. The study showed anti-tumor activity, particularly in ovarian and urothelial cancers, with an overall response rate of 22% for ovarian patients and 67% for urothelial patients. The safety profile appears favorable, with low incidence of serious side effects. Enrollment in the expansion cohorts at a recommended dose of 6.5mg/m2 every other week continues. A conference call will be held today at 8:30 a.m. ET.
Bicycle Therapeutics plc (NASDAQ: BCYC) announced management's participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 10:00 a.m. ET. The event will be accessible via a live webcast on Bicycle's website, with an archived replay available for 90 days afterwards. Bicycle Therapeutics specializes in developing innovative therapeutics utilizing its proprietary bicyclic peptide technology, focusing on drug candidates for underserved diseases.
Bicycle Therapeutics (NASDAQ: BCYC) reported continued clinical progress, including dosing the first patient in the Phase I/II study of BT5528. The expansion of collaboration with Genentech triggered a $10 million payment expected in Q3 2022. As of June 30, 2022, the company had cash and equivalents of $372.8 million, providing financial runway into 2025. R&D expenses rose to $19.9 million from $11.7 million year-over-year, while G&A expenses increased to $11.8 million. Net loss for the quarter was $26.8 million, or $(0.90) per share, compared to a loss of $17.9 million a year earlier.
Bicycle Therapeutics plc (NASDAQ: BCYC) announced the publication of an article in Bioconjugate Chemistry regarding the use of tris-Gold complexes to enhance the chemical diversity of its proprietary Bicycle peptides. The research showcases a method for constructing constrained Bicycle peptides, which may be beneficial for future targets. CEO Kevin Lee highlighted this publication as a sign of the company's robust research capabilities. Bicycle continues clinical trials for several candidates, including BT5528 and BT8009, targeting important tumor antigens.
Circle Pharma has appointed Paul Park as its Chief Business Officer to advance its lead program, an orally bioavailable Cyclin A inhibitor, towards clinical trials. Park brings extensive experience from previous roles at Ionis Pharmaceuticals and Amgen, where he led significant business transactions. The company aims to leverage its macrocycle platform to expand its pipeline, focusing on oncology therapeutics targeting cyclin proteins, which play a critical role in cancer cell regulation. Circle’s approach addresses unmet clinical needs in serious diseases.
Bicycle Therapeutics (NASDAQ: BCYC) reported the publication of preclinical data on BT7480, a novel tumor-targeted immune cell agonist, in the Journal of Medicinal Chemistry. BT7480 targets Nectin-4 and activates CD137, demonstrating unique properties such as small size and potent immune activation. This molecule is currently in Phase I development with ongoing dose escalation. Bicycle aims to advance its pipeline with BT7480 as a potential clinical candidate, leveraging its proprietary Bicycle technology to enhance anti-tumor immunity.
Bicycle Therapeutics (NASDAQ: BCYC) announced that Genentech, part of the Roche Group, has exercised its second expansion option under a 2020 collaboration agreement, initiating a new program to develop Bicycle®-based immuno-oncology therapies. This move entails a $10 million payment to Bicycle, marking significant progress in their strategic partnership. The collaboration focuses on discovering and pre-clinically developing novel therapeutics targeting multiple cancer types. Both companies are optimistic about the potential of Bicycle technology in advancing cancer treatment.
Bicycle Therapeutics (NASDAQ: BCYC) announced the dosing of the first patient in the Phase I/II trial of BT5528, a second-generation Bicycle Toxin Conjugate designed to target EphA2. Following a successful Phase I dose escalation, the expansion phase aims to evaluate BT5528's clinical activity in various cancer types, administering a recommended Phase II dose of 6.5 mg/m2 biweekly. Initial data, including safety and anti-tumor activity, is anticipated to be released next quarter. The trial includes up to 56 patients in the initial cohorts.